PolyPid (NASDAQ:PYPD) Issues Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12, FiscalAI reports.

Here are the key takeaways from PolyPid’s conference call:

• PolyPid said its rolling NDA submission for D-PLEX100 is underway, with the remaining clinical module expected to be filed imminently, and that the product could qualify for priority review if the FDA accepts the submission.
• Management said U.S. strategic partnership discussions are in late stages, with the goal of supporting a commercial launch in Q1 2027 and prioritizing a partner with strong hospital sales capabilities.
• The company highlighted encouraging data from SHIELD II, including a 64% relative risk reduction in severe wound events, which it believes strengthens the product’s health-economic case for hospitals and payers.
• PolyPid said it is advancing its European MAA strategy and plans to submit the application to the EMA in the third quarter of 2026, subject to upcoming rapporteur meetings.
• Financially, the company reported a Q1 net loss of $7.7 million, cash and short-term deposits of $10.9 million at quarter-end, and said it fully repaid its remaining loan facility after quarter end, leaving it debt-free and funded into the second half of 2026.

PolyPid Price Performance

NASDAQ PYPD traded up $0.14 on Friday, hitting $4.52. 98,214 shares of the company’s stock were exchanged, compared to its average volume of 58,834. The firm’s 50-day moving average price is $4.39 and its two-hundred day moving average price is $4.24. PolyPid has a fifty-two week low of $2.44 and a fifty-two week high of $5.12. The firm has a market cap of $86.30 million, a price-to-earnings ratio of -2.33 and a beta of 1.41.

Hedge Funds Weigh In On PolyPid

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its position in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares during the period. HighTower Advisors LLC acquired a new position in PolyPid during the 4th quarter worth approximately $44,000. Jane Street Group LLC acquired a new position in PolyPid during the 4th quarter worth approximately $66,000. XTX Topco Ltd increased its position in PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in PolyPid during the 4th quarter worth approximately $451,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Weiss Ratings downgraded PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research note on Wednesday, February 11th. Finally, Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.25.

About PolyPid

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.